DCGI gives permission for approval of protocol for a multi-center two arm prospective, phase-II open labeled randomized controlled trial of convalescent plasma in COVID-19 patients.
DCGI gives permission for approval of protocol for a multi-center two arm prospective, phase-II open labeled randomized controlled trial of convalescent plasma in COVID-19 patients.
The cabinet has approved four schemes which totally include Rs 13,760 crore to promote the domestic production of active pharmaceutical ingredients (APIs) and medical devices in the country and their exports.
Foreign direct investment (FDI) is continuously declining in India. It is second time since 2014, there is a steady decline reported in 2019-20. It was Rs. 9994 crores in 2014-15 and declined to Rs. 2496 crore in 2019-2020 as reported by department of pharmaceuticals.